Oncolytics Biotech Inc.
ONC.TO
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 15.97% | 8.88% | -97.31% | 5.44% | 4.27% |
| Total Depreciation and Amortization | -5.17% | -25.88% | -27.23% | 0.26% | 0.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 550.99% | 233.66% | 126.82% | 143.81% | -84.01% |
| Change in Net Operating Assets | -199.36% | -2,328.98% | -161.14% | 15.49% | 111.22% |
| Cash from Operations | 20.65% | 18.27% | -24.52% | 21.20% | 20.92% |
| Capital Expenditure | -- | -- | -95.45% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -95.45% | -100.47% | -102.24% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -56.92% | 0.00% | 3.85% | 21.57% | 35.00% |
| Issuance of Common Stock | 191.43% | 273.16% | -- | -98.79% | -44.60% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -550.38% | -230.99% | -106.20% | 84.30% | -3.15% |
| Cash from Financing | 169.06% | 270.10% | 86.29% | -100.80% | -47.48% |
| Foreign Exchange rate Adjustments | -332.76% | -104.10% | 221.76% | -148.48% | 165.45% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 85.91% | 88.69% | 29.90% | -123.00% | -383.13% |